Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) shot up 4.2% on Thursday . The company traded as high as C$0.25 and last traded at C$0.25. 44,980 shares traded hands during trading, an increase of 124% from the average session volume of 20,061 shares. The stock had previously closed at C$0.24.
Devonian Health Group Trading Up 4.2 %
The stock has a market capitalization of C$37.06 million, a price-to-earnings ratio of -12.50 and a beta of 1.28. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The business’s 50-day simple moving average is C$0.20 and its two-hundred day simple moving average is C$0.18.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Further Reading
- Five stocks we like better than Devonian Health Group
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Overbought Stocks Explained: Should You Trade Them?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
